Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14714350 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL15635071 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL8205840 | 0.92 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL5832813 | 0.92 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL12328185 | 0.92 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL5549676 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL5549677 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL8870748 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL12295954 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL16432771 | 0.87 | CHRM2 (0.40) | CHRM2CHRM1CHRM3PREPEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| EP-2747764-B1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND USE OF SAME | FORSCHUNGSVERBUND BERLIN EV (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-9242985-B2 | Structural mimetics of proline-rich peptides and use thereof | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20140100217-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2014-04-10 | — | — | US | disclosed |
| WO-2013030111-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND USE THEREOF | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2013-03-07 | — | — | WO | disclosed |
| EP-2561873-A1 | Structural mimetics of proline-rich peptides and use of same | Forschungsverbund Berlin e.V. (DE) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100217-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE | NPY1R, NPR1, NPY2R | CHRM2 2195/4885CHRM1 1311/4885CHRM3 3692/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CHRM2 4401/4885CHRM1 3662/4885CHRM3 4107/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | CHRM2 4401/4885CHRM1 3662/4885CHRM3 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.